On Tuesday, Shares of KaloBios Pharmaceuticals Inc (NASDAQ:KBIO), gained 26.16% to $2.17.
Harvard Apparatus Regenerative Technology Inc. (HART), Arena Pharmaceuticals Inc. (ARNA), Aeterna Zentaris Inc. (AEZS), and KaloBios Pharmaceuticals Inc. (KBIO) are four tickers in the health-care space taking part in the bustling M&A activity the sector practiced in the past year. The sector faced recent pressure caused by price gouging and reactions from politicians against ‘big pharma’ monopolies. However, the health-care sector has thrived nonetheless with in unfavorable economic conditions and has outperformed all other sectors. This presents investors with opportunities for spotting takeover candidates while earning noteworthy returns from holding the large caps as well.
KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. The company’s product candidates comprise KB004, which is in a Phase II clinical trial for the treatment of myelodysplastic syndrome and myelofibrosis; and KB003 that accomplished Phase II clinical trial to treat chronic myelomonocytic leukemia, an orphan oncology indication. KaloBios Pharmaceuticals, Inc. was founded in 2000 and is headquartered in South San Francisco, California.
Shares of Visa Inc (NYSE:V), declined -0.01% to $78.82, during its last trading session.
Bottomline Technologies, declared a planned alliance with Visa Inc. (NYSE:V) that will create the optimum way for businesses to pay and get paid. Visa’s commercial card solution, Visa Payables, and Bottomline’s payment network, Paymode-X, join to create Paymode-X with Visa Payables.
Paymode-X with Visa Payables advances the two companies’ shared vision for business payment automation. The combined solution draws upon the strength of two large established networks, best-of-breed commercial card and payment capabilities and a proprietary vendor onboarding methodology. Paymode-X with Visa Payables will be easy for payers and vendors to join and use, accelerating and maximizing opportunities for payment efficiency, security and financial gains.
“The combination of Visa Payables and Paymode-X will bring corporate clients a seamless experience that simplifies payment automation and maximizes cost savings, efficiency and security,” said Brian Triplett, SVP and global head of Commercial Solutions, Visa. “By integrating Visa’s digital payment capabilities with Paymode-X, Visa continues to enhance our suite of commercial solutions, empowering corporate buyers and suppliers to take advantage of the benefits of electronic payments.”
Visa Inc., a payments technology company, operates as a retail electronic payments network worldwide. The company facilitates commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Finally, Shares of Bristol-Myers Squibb Co (NYSE:BMY), ended its last trade with 1.09% loss, and closed at $65.73.
Bristol-Myers Squibb Company (BMY) recently declared that the U.S. Food and Drug Administration (FDA) has accepted for filing and precedingity review a supplemental Biologics License Application (sBLA) for Opdivo for the treatment of patients with advanced renal cell carcinoma (RCC) who have received preceding anti-angiogenic therapy. The FDA formerly granted Opdivo Breakthrough Therapy Designation for this indication, underscoring the critical need for new treatment options for patients with advanced RCC who have received preceding therapy. The projected FDA action date is March 16, 2016.
Michael Giordano, M.D., senior vice president, head of Oncology Development, Bristol-Myers Squibb, commented, “There remains a noteworthy unmet medical need for advanced renal cell carcinoma patients who have received preceding therapy and are often repeatedly treated with agents that are similar in mechanism. We are happy the FDA has accepted our sBLA for Opdivo in RCC, and we will continue to work with urgency to bring Opdivo to patients with this cancer.”
This sBLA submission is based on CheckMate -025, a Phase 3 study that evaluated the overall survival of Opdivo in patients with formerly treated advanced RCC as compared to everolimus, a current standard of care in this patient population. The trial was stopped early in July 2015 because an assessment conducted by the independent Data Monitoring Committee (DMC) concluded that the study met its primary endpoint of overall survival. Data from CheckMate -025 were recently presented at the 2015 European Cancer Congress and simultaneously published in The New England Journal of Medicine.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.